In addition, pharmacological inhibition of CaCC activity of ANO1 reduced cell viability in HNSCC, esophageal squamous cell carcinoma (ESCC) and breast cancer cells via inhibition of epidermal growth factor receptor (EGFR) and calmodulin-dependent protein kinase II (CAMKII) signaling [16]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.